Key result
Dantrolene stabilizes RyR2 to prevent calcium leak, showing therapeutic potential for HF and lethal arrhythmias.
Dantrolene shows potential as a novel therapeutic agent for heart failure and lethal arrhythmias by targeting RyR2 to prevent calcium leak.
Dantrolene may extend RyR2 stabilization to HF and arrhythmias; leaves open clinical efficacy and requires prospective trials before any practice change.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shigeki Kobayashi (2013) conducted a review in Heart failure and lethal arrhythmia (CPVT). Dantrolene was evaluated. Dantrolene stabilizes inter-domain interactions within the ryanodine receptor, preventing abnormal calcium leak and showing potential as a novel therapeutic agent for heart failure and lethal arrhythmias.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: